Trials / Conditions / Retinitis Pigmentosa (RP)

Retinitis Pigmentosa (RP)

22 registered clinical trials studyying Retinitis Pigmentosa (RP) — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenet NCT07282457	Zhongmou Therapeutics	Phase 1 / Phase 2
Not Yet Recruiting	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher NCT07290530	Nacuity Pharmaceuticals, Inc.	Phase 3
Recruiting	Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration NCT07266584	Science Corporation	N/A
Not Yet Recruiting	Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment NCT07341763	University of Waterloo	N/A
Not Yet Recruiting	Wide Field OCTA in Ocular Diseases NCT07298174	IRCCS San Raffaele	—
Not Yet Recruiting	UGX202 Injection in Patients With Advanced Retinitis Pigmentosa NCT07311863	Suzhou UgeneX Therapeutics Co., Ltd.	EARLY_Phase 1
Not Yet Recruiting	Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations NCT07265895	IRCCS San Raffaele	—
Recruiting	Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Ho NCT07292987	Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts	N/A
Recruiting	Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients NCT07126470	Zhongshan Ophthalmic Center, Sun Yat-sen University	N/A
Not Yet Recruiting	Retinal Investigation Using Optos OCT Device NCT06846151	Optos, PLC	N/A
Not Yet Recruiting	Functional Assessments in Vision Impairment NCT06908161	Center for Eye Research Australia	—
Recruiting	A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) NCT06789445	BlueRock Therapeutics	Phase 1 / Phase 2
Active Not Recruiting	Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases NCT07341919	Rubens Camargo Siqueira	Phase 1 / Phase 2
Recruiting	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH NCT06627179	Laboratoires Thea	Phase 2
Recruiting	Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies NCT06787482	Ace Cells Lab Limited	Phase 1 / Phase 2
Enrolling By Invitation	Subthreshold Micropulse Laser Therapy (SML) in Retinitis Pigmentosa NCT07088705	Marta P. Wiącek	N/A
Active Not Recruiting	Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases NCT07348588	Centro de Pesquisa Rubens Siqueira	Phase 1 / Phase 2
Unknown	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP) NCT04763369	Jinnah Burn and Reconstructive Surgery Centre, Lahore	Phase 2
Unknown	Retrospective Natural History Study of Retinitis Pigmentosa NCT03975543	SparingVision	—
Completed	Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT NCT02575430	QLT Inc.	—
Completed	Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa NCT02320812	jCyte, Inc	Phase 1 / Phase 2
Completed	Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Ep NCT01543906	QLT Inc.	Phase 1